{"schema_version":"secwatch.filing_event.v1","accession":"0001437749-26-017063","form_type":"8-K","ticker":"ETON","cik":"0001710340","company_name":"Eton Pharmaceuticals, Inc.","filed_at":"2026-05-14T20:16:28+00:00","discovered_at":"2026-05-14T20:18:00.261608+00:00","generated_at":"2026-05-14T20:49:04.039885+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Eton Pharma Q1 product sales $24.3M (+73% YoY); raises FY2026 guidance to >$120M","bullets":["Q1 product sales $24.3M (+73% YoY); GAAP diluted EPS $0.05, non-GAAP diluted EPS $0.14, Adj. EBITDA $5.7M (24% margin)","Raises full-year 2026 revenue guidance to >$120M from prior $110M; expects ≥30% Adj. EBITDA margin","Launched DESMODA (FDA-approved oral desmopressin solution); acquired and relaunched HEMANGEOL on May 1","Initiated ET-700 clinical study (extended-release zinc acetate for Wilson disease); FDA cleared INCRELEX label harmonization study","Net income of $1.6M vs net loss of $1.6M in Q1 2025; cash $19.7M after $14M HEMANGEOL acquisition"],"urls":{"canonical":"https://secwatch.observer/filing/0001437749-26-017063","json":"https://secwatch.observer/filing/0001437749-26-017063.json","markdown":"https://secwatch.observer/filing/0001437749-26-017063.md","text":"https://secwatch.observer/filing/0001437749-26-017063.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1710340/000143774926017063/0001437749-26-017063-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1710340/000143774926017063/eton20260322_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-14T20:49:04.039885+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"c5de609c1c26d3099100eb6b7f575d1c71e9a096","claim":"Eton Pharmaceuticals, Inc. reported the quarter ended March 31, 2026 results: revenue $24.3 million, EPS $0.05. Guidance raised.","evidence_excerpt":"Q1 2026 product sales of $24.3 million, representing 73% growth over Q1 2025 ● Raising full year revenue guidance - now expect 2026 revenue to exceed $120 million, up from previous guidance of $110 million ● Q1 2026 fully diluted GAAP EPS of $0.05","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1710340/000143774926017063/0001437749-26-017063-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the quarter ended March 31, 2026"},{"label":"Revenue","value":"$24.3 million"},{"label":"EPS","value":"$0.05"},{"label":"Guidance","value":"raised"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}